MoveMed

What MoveMed does

MoveMed is a privately held digital health company founded in 2019 by University of Cambridge researchers to commercialize smartphone-based neurological assessment technology. The company offers a single integrated mobile application that delivers a suite of gamified performance-based tests (Fast Tap, Hold, Typing, Stand and Walk) capturing objective digital biomarkers of upper and lower limb function alongside patient-reported outcomes. The platform is designed to enable smaller, faster, and more cost-effective clinical trials by providing statistically powerful endpoint measurement, with validation published in JMIR Neurotechnology (2024) under COSMIN guidelines and alignment to FDA and EMA digital endpoint guidance.

MoveMed serves clinical research organizations, pharmaceutical companies, and medical device manufacturers conducting trials in neurological, musculoskeletal, and cardiovascular indications, with current deployments anchored in two NIHR-funded Phase 3 randomized controlled trials in degenerative cervical myelopathy (POLYFIX-DCM, 394 patients, and RECEDE-Myelopathy), coordinated through Cambridge Clinical Trials Unit. The app is distributed globally on iOS and Android with integration to Apple HealthKit and Google Fit, and the company operates a dual-channel go-to-market combining enterprise direct sales (discovery sessions and demos) with community-led engagement through patient advocacy groups such as Myelopathy.org and professional networks including AO Spine RECODE-DCM.

Revenue mechanics rely on clinical trial software licensing structured as recurring subscriptions, supplemented by research study participation services. Named customers include Cambridge University Hospitals NHS Foundation Trust, University of Sydney, MediciNova, NYU Langone Health, and Amazon. No pricing, ARR, revenue figures, or external funding rounds are publicly disclosed. The leadership team comprises five C-suite executives (CEO, CSO, CTO, CFO, CMO), two VPs (Sales and Partnerships, Product), and two advisors, consistent with a founder-led early-stage commercial organization.

Name

MoveMed

Legal name

MoveMed

Website

https://movemed.io

Company type

Private

Founded year

2019

Operating status

Operating

Headcount range

1–10 employees

Short description

MoveMed is a Cambridge, UK-based digital health company founded in 2019 that provides a smartphone-based platform combining digital biomarkers and patient-reported outcomes to enable smaller, faster, and more cost-effective clinical trials for neurological conditions. It serves pharmaceutical companies, CROs, and medical device manufacturers running trials in DCM, MS, Parkinson's, and stroke.

Ownership category

akta.pro rank

Product category

Clinical Trial Technology

NAICS

Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)

SIC

Services-Health Services (8000)

akta.pro primary industry

Remote Therapeutic Monitoring (RTM) & Digital Rehabilitation Platforms (HLALABAK)

akta.pro secondary industries

Decentralized & Hybrid Trial Site Services (Home Health/Nursing) (HLAGACAH), Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ)

Keywords

• Digital outcome measures
• Clinical trial endpoints
• Digital biomarkers
• Neurological assessments
• Patient-reported outcomes

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Clinical Trial Software Licensing: MoveMed provides its digital assessment platform to pharmaceutical companies and research institutions conducting clinical trials. The company licenses its technology as a measurement tool embedded within trial protocols.
2. Research Study Participation: The company conducts research studies (EMPOWER trial, EMPOWER Study) where participants use the app, generating data to validate the technology across multiple neurological conditions.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

MoveMed provides a smartphone-based digital assessment platform for clinical trials that combines patient-reported outcomes with digital biomarkers to measure neurological function (finger dexterity, gait, stability, typing). The app enables decentralized trial participation with real-time data capture and dashboard analytics for sponsors. The platform is validated against FDA and EMA guidance and supports use as regulatory-grade clinical trial endpoints.

Product overview

MoveMed is a single unified smartphone application designed for clinical trial outcomes measurement. The core product is the MoveMed App, which delivers a battery of performance-based tests (Fast Tap Test, Hold Test, Typing Test, Stand and Walk Test) to objectively measure upper and lower limb function. The app serves as both the patient interface for completing assessments and the data collection platform, with built-in integration to operating system health measures (Apple HealthKit, Google Fit) and real-time dashboards for trial oversight. No separate modules, add-ons, or companion products are offered—all functionality is contained within the single MoveMed App.

Differentiator

Problem solved

Functional benefit

Products and services

• MoveMed Digital Assessment Platform

Quantifiable outcome

• ICC values 0.68-0.95 across all tests demonstrating moderate to excellent test-retest reliability
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature8 records

Partnerships

Four partnerships are on record, tiered core.

• University of CambridgecoreStrategic or Co-development PartnerMoveMed was founded by researchers at the University of Cambridge. The company originated from academic research and continues collaboration with Cambridge investigators. The study has received ethical approval from the University of Cambridge Human Biology Ethics Review Board.
• Myelopathy.orgcoreStrategic or Co-development PartnerMyelopathy.org is a DCM charity that supports the MoveMed research study. Iwan Sadler, Co-Founder and Trustee of Myelopathy.org and living with DCM, provides patient perspective and advocacy for MoveMed.
• AO Spine RECODE-DCMcoreStrategic or Co-development PartnerMoveMed team members led the AO Spine RECODE-DCM initiative, which established standardized frameworks for what should be measured, how and when in DCM clinical trials. This established the measurement science foundation for MoveMed.
• Cambridge Clinical Trials UnitcoreStrategic or Co-development PartnerMoveMed is implemented as a key digital assessment tool in NIHR-funded Phase 3 RCTs (POLYFIX-DCM and RECEDE-Myelopathy) coordinated by Cambridge Clinical Trials Unit, demonstrating enterprise-level validation.

Scale indicators4 records

Recent moves4 records

Expansion highlights5 records

Direct peers

• Castor: Castor provides an electronic data capture and decentralized clinical trial platform used by pharma and academic sponsors — comparable to MoveMed as an enterprise SaaS tool embedded in trial workflows.
• VivoSense: VivoSense provides digital clinical measures and wearable/sensor-based biomarkers for regulated clinical trials — a close peer in objective endpoint measurement for pharma and CRO customers.
• Medable: Medable operates a decentralized clinical trial platform that includes eCOA and remote data capture — directly comparable to MoveMed's B2B SaaS model embedded in decentralized trial workflows.
• IXICO: IXICO develops digital biomarkers and imaging analytics for neurological clinical trials — directly comparable to MoveMed's neuroscience-focused endpoint measurement positioning and trial sponsor customer base.
• Koneksa Health: Koneksa Health develops digital biomarker strategies and remote patient monitoring tools for clinical trials — a focused peer in pharma-grade digital endpoint measurement.
• ActiGraph: ActiGraph is a leading provider of wearable digital health technology and validated digital biomarkers for clinical research — overlapping strongly with MoveMed's objective measurement value proposition for trial sponsors.
• THREAD Research: THREAD provides a decentralized clinical trial platform with electronic clinical outcome assessment capabilities — competing for the same pharma trial endpoint budget that MoveMed targets.

Emerging players

• Curebase: Curebase enables decentralized and hybrid clinical trials with virtual site operations — adjacent to MoveMed's decentralized trial use case, particularly relevant for sponsor-side deployment models.
• Evidation Health: Evidation aggregates patient-generated health data from wearables and apps for research and outcome measurement — an emerging player in the digital biomarker space that intersects with MoveMed's remote measurement approach.

Broad incumbents

• Clario: Clario (formed from ERT and Bioclinica) is a large incumbent in clinical trial endpoint technology including eCOA, imaging, and digital biomarkers — a broader portfolio competitor to MoveMed's specialized digital biomarker focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MoveMed